

This Page Is Inserted by IFW Operations
and is not a part of the Official Record.

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

TECH CENTER 1600/2500

AUG 20 2002

RECEIVED

#11
9/12/03
82Applicant: ANAND *et al.*

U.S. Serial No.: 09/998,115 ✓

Examiner: Unknown

Filing Date: November 30, 2001 ✓

Group Art Unit: 614

Title: 1,4-DISUBSTITUED PIPERAZINE DERIVATIVES USEFUL AS URO-
SELECTIVE α_1 -ADRENOCEPTOR BLOCKERS ✓Assistant Commissioner of Patents
Washington, D.C. 20231COPY OF PAPERS
ORIGINALLY FILED**TRANSMISSION OF PRIORITY DOCUMENT**

Applicants transmit herewith a certified copy of Indian Patent Application No.
1097/Del/2000 filed 30 November 2000 (30.11.2000) to which priority is claimed herein.

Respectfully submitted,

RANBAXY LABORATORIES LIMITED

By:

Jayadeep R. Deshmukh
Vice President - Intellectual Property

Dated: 8 August 2002

Ranbaxy Pharmaceuticals Inc.
600 College Road East, Suite 2100
Princeton, New Jersey 08540
Tel.: 609-720-5608
Fax: 609-514-9779

THIS PAGE BLANK (USPTO)



#11

RECEIVED

AUG 20 2002

TECH CENTER 1600/2900

**GOVERNMENT OF INDIA
MINISTRY OF COMMERCE & INDUSTRY
PATENT OFFICE, DELHI BRANCH,
W-5, WEST PATEL NAGAR,
NEW DELHI-110 008.**

I the undersigned being an officer duly authorized in accordance with the provision of the Patent Act, 1970 hereby certify that annexed hereto is the true copy of the Application and Complete Specification and Drawing Sheets filed in connection with Application for Patent No.1097/Del/00 dated 30th November 2000.

Witness my hand this 04th day of June 2002.


(H.C. BAKSHI)

Deputy Controller of Patents & Designs.

THIS PAGE BLANK (USPTO)

FORM 1

Govt. of India Patent Office
New Delhi
Received By *5200/1000*
Cheque No. *1000* / *1000* / *1000* D.D.
on *30 NOV 2000*
Vide Entry No. *3252* in the
Register of Valuations
APATENT *1000*
Cheque

THE PATENTS ACT, 1970
(39 of 1970)

APPLICATION FOR GRANT OF A PATENT

(See Sections 5 (2), 7, 54 and 135 and rule 33A)

- 1 We, **RANBAXY LABORATORIES LIMITED**, a Company incorporated under the Companies Act, 1956 of 19, Nehru Place, New Delhi - 110 019, India
2. hereby declare –
- (a) that we are in possession of an invention titled **"PROCESSES FOR THE SYNTHESIS OF 1,4-DISUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS URO-SELECTIVE α_1 -ADRENOCEPTOR BLOCKERS"**
- (b) that the Complete Specification relating to this invention is filed with this application.
- (c) that there is no lawful ground of objection to the grant of a patent to us.
3. Further declare that the inventors for the said invention are
- a. NITYA ANAND#
b. SANJAY JAIN**
c. NEELIMA SINHA***
d. ANITA CHUGH*
e. LAXMINARAYAN G. HEGDE*
- *of Ranbaxy Laboratories Limited, Plot No. 20, Sector-18, Udyog Vihar Industrial Area, Gurgaon – 122001 (Haryana), India,
#of B-62, Nirala Nagar, Lucknow-226001, India
**of 80, Nazar Bagh, Lucknow-226001, India
***of C/o Dr. Neeraj Sinha, Scientist, SA/S-8, N.B.R.I. Guest House, 21, Gokhle Marg, Lucknow-226001, India
all Indian Nationals.
4. That we are the assignee or legal representative of the true and first inventors.
5. That our address for service in India is as follows:

DR. BRIJ KHERA
Associate Director – Intellectual Property
Ranbaxy Laboratories Limited
Plot No.20, Sector – 18,
Udyog Vihar Industrial Area,
Gurgaon – 122001 (Haryana).
INDIA.
Tel. No. (91-124) 6343126, 6342001-10
Fax No. (91-124) 6342027

6. Following declaration was given by the inventors in the convention country:
We, NITYA ANAND#, SANJAY JAIN**, NEELIMA SINHA***, ANITA CHUGH*,
LAXMINARAYAN G. HEGDE*, JANG BAHADUR GUPTA*,
*of Ranbaxy Laboratories Limited, Plot No. 20, Sector-18, Udyog Vihar Industrial Area,
Gurgaon – 122001 (Haryana), India,
#of B-62, Nirala Nagar, Lucknow-226001, India
**of 80, Nazar Bagh, Lucknow-226001, India
***of C/o Dr. Neeraj Sinha, Scientist, SA/S-8, N.B.R.I. Guest House, 21, Gokhle Marg,
Lucknow-226001, India
all Indian Nationals, the true and first inventors for this invention in the convention country
declare that the applicants herein, **Ranbaxy Laboratories Limited**, 19, Nehru Place, New
Delhi - 110 019, India, is our assignee or legal representative.

- a. Nitya Anand
(NITYA ANAND)
b. Sanjay Jain
(SANJAY JAIN)
c. Neelima Sinha
(NEELIMA SINHA)
d. Anita Chugh
(ANITA CHUGH)
e. Laxminarayan G. Hegde
(LAXMINARAYAN G. HEGDE)
f. Jang Bahadur Gupta
(JANG BAHADUR GUPTA)

7. That to the best of our knowledge, information and belief the fact and matters stated herein are correct and that there is no lawful ground of objection to the grant of patent to us on this application.
8. Followings are the attachment with the application:
a. Complete Specification (3 copies)
b. Drawings (3 copies)
c. Statement and Undertaking on FORM – 3
d. Fee Rs.5,000/- (Rupees Five Thousand only..) in cheque bearing No. 672178 dated 29.11.2000 on ANZ Grindlays Bank, New Delhi.

We request that a patent may be granted to us for the said invention.

Dated this 29th day of November, 2000.

For Ranbaxy Laboratories Limited

S K
(S K PATAWARI)
Company Secretary

FORM 2

The Patents Act, 1970
(39 of 1970)

COMPLETE SPECIFICATION
(See Section 10)

1037 DEL 00
30 NOV
DEC 2000

**PROCESSES FOR THE SYNTHESIS OF 1,4-DISUBSTITUTED
PIPERAZINE DERIVATIVES USEFUL AS URO-SELECTIVE
 α_1 -ADRENOCEPTOR BLOCKERS**

ORIGINAL

RANBAXY LABORATORIES LIMITED
19, NEHRU PLACE, NEW DELHI - 110019
(A Company incorporated under the Companies Act, 1956)

The following specification particularly describes and ascertains the nature of this invention and the manner in which it is to be performed:

The present invention relates to a process for the synthesis of 1,4-disubstituted piperazine derivatives of Formula I, as shown in the accompanied drawings and their pharmaceutically acceptable acid addition salts having excellent uro-selective α_1 -adrenoceptor antagonistic activity exceeding those of previously described compounds. The compounds of the present invention hold promise for treating the symptoms of benign prostatic hyperplasia (BPH). The invention also relates to pharmaceutical compositions containing the compounds and method of treating the symptoms of benign prostatic hyperplasia using the compounds.

Benign prostatic hyperplasia (BPH) is a common disease in aging males and a substantial percentage of men with BPH develop a bladder obstruction. The obstruction caused by BPH is thought to be attributable to two main components i.e. a static component related to enlarged prostatic tissue mass and a dynamic component involving excessive contraction of prostate and urethra. The most successful therapies are based on α -adrenergic receptor antagonism and androgen levels modulation by 5α -reductase inhibitors. 5α -reductase inhibitors are of limited effectiveness in terms of immediate symptomatic and urodynamic relief. α_1 -adrenergic receptors antagonists appear to be much more effective and provide immediate subjective symptomatic improvements and are, therefore, the preferred modalities of treatment in the control of symptoms of benign prostatic hyperplasia. α_1 -Adrenoceptors are also present in blood vessels and play an important role in the regulation of blood pressure. Thus α_1 -adrenoceptor antagonists are of particular importance as antihypertensive agents and are likely also to have a beneficial effect on lipid dysfunction and insulin resistance, which are commonly associated with essential hypertension.

The drugs most often used for BPH are the long acting α_1 -adrenoceptor antagonists, terazosin, doxazosin and tamsulosin, as shown in Formulae II, III and IV, respectively, in the accompanied drawings. However, these drugs are associated with vascular side effects (e.g. postural hypertension, syncope, dizziness, headache etc.) due to lack of selectivity of action between prostatic and vascular α_1 -adrenoceptors.

Over the past decade, there has been an intensive search for "uroselective" α_1 -adrenoceptor antagonists for BPH, which would avoid the cardiovascular side effects, associated with currently used drugs. Clearly α_1 -adrenoceptor antagonists which have inherently greater selectivity for prostatic α_1 -adrenoceptors offer the potential of increased urodynamic benefits. This underscores the importance of the discovery of antagonists which will confer urodynamic improvement without the side effects associated with existing drugs.

Recently, three subtypes of α_1 -receptors namely α_{1A} , α_{1B} , and α_{1D} have been identified which can provide a key development to improve the pharmacological selectivity of α_1 blockers. These subtypes have different tissue distribution with the α_{1A} receptors predominating lower urinary tract tissue and less prevalent in the vasculature. This makes it possible to develop agents with selective action against pathological urodynamic states. A uroselective α_{1A} -antagonist could have greater efficacy if dose escalation is not limited to cardiovascular side effects and a more complete blockade of prostatic α_1 -adrenoceptors could be attained. Compounds have been evaluated for potency against agonist or stimulation-induced increase in urethral pressure relative to blood pressure reduction or blockade of agonist-induced blood pressure. Many selective antagonists have been described by Hieble et. al in Exp opin Invest Drugs; 6, 367-387 (1997) and by Kenny et. al. in J. Med. Chem.; 40, 1293 - 1315 (1997). Structure activity relationships in many of these structural series have been studied in details and numerous highly selective compounds have been identified.

The present invention is directed towards synthesis of novel α_1 -antagonists, namely, 1,4-disubstituted piperazine compounds, with greater selectivity of action against α_{1A} -adrenoceptors and which would thus offer relief from the symptoms of BPH.

There are many description in the literature about the pharmacological activities associated with phenyl piperazines, Eur. J. Med. Chem. - Chimica Therapeutica, 12, 173-176 (1977), describes substituted trifluoromethyl phenyl piperazines having cyclo-imido alkyl side chains, shown as Formula V in the accompanied drawings. These compounds are potential anorectic agents with no CNS side effects. Other

related compounds which have been prepared as anxiolytic, neuroleptic, anti-diabetic and anti-allergic agents are described in the following references:

- Yukihiro et al; PCT Appl. WO 98/37893 (1998).
- Steen et al; *J. Med. Chem.*, 38, 4303-4308 (1995).
- Ishizumi et al. *Chem. Pharm. Bull*; 39 (9), 2288-2300 (1991).
- Kitano et al; JP 02-235865 (1990).
- Ishizumi et al; US 4,598,078 (1986).
- New et. al; *J. Med. Chem*, 29, 1476-1482 (1986).
- Shigeru et al, JP 60-204784 (1985).
- New et al, US 4,524,206 (1985).
- Korgaonkar et al; *J. Indian Chem. Soc.*, 60, 874-876 (1983)

The synthesis and pharmacology of some 2-[3-(4-aryl-1-piperazinyl) propyl]-1H-benz(de) isoquinolin-1,3-(2H)-diones/2,5-pyrrolidinediones (*J. Indian. Chem. Soc.*, Vol., LXIII, 529-530 (1986), of N-(N⁴-aryl-N¹-piperazinylmethyl)-4-(4-methoxyphenyl)piperidine-2,6-diones [*J. Indian Chem. Soc.*, Vol. LV, 819-821 (1978)], and of N-(N⁴-aryl-piperazinylalkyl)-phthalimides (*J. Indian. Chem. Soc.*, Vol. LVI, 1002-1005 (1979)) have been reported. The compounds were shown to exhibit antihypertensive and CNS depressant activity in experimental animals.

However, none of the above mentioned references disclose or suggest the selective α_1 -adrenoceptor blocking activity of the compounds disclosed therein and thus their usefulness in the treatment of symptoms of benign prostate hyperplasia did not arise.

The earlier synthesis of various 1-(4-aryl-piperazin-1-yl)-3-(2-oxo-pyrrolidin-1-yl)piperidin-1-yl)alkanes and their usefulness as hypotensive and antischemic agents is disclosed in unpublished Indian Patent applications Del/496/95 (March 03, 1995), Del/500/95 (March 21, 1995) and Del/96/96 (March 29, 1996) by the inventors herein and are hereby cited as references. These compounds had low α_1 -adrenergic blocking activity (pKi-6 as compared to >8 of the known α_1 -antagonists such as prazosin), and practically no adrenoceptor sub class selectivity for α_{1A} Vs. α_{1B} or

α_{1D} -adrenoceptors. Also the synthesis of 1-(4-arylpiperazin-1-yl)- ω -[N-(α , ω -dicarboximido)]-alkanes useful as uro-selective α_1 -adrenoceptor blockers are disclosed in US Patent Nos. 6,083,950 and 6,090,809 filed by the inventors herein. These compounds had good α_1 -adrenergic blocking activity and selectivity and one of the compounds is in phase II clinical trials.

It has now been discovered that structural modification of these compounds from glutarimide to tetrahydrophthalimide enhances the adrenoceptor blocking activity and also greatly increases the selectivity for α_{1A} in comparison to α_{1B} - adrenoceptor blocking activity, an essential requirement for compounds to be good candidates for treatment of BPH.

An object of the present invention is to provide a process for the synthesis of aryl-piperazine derivatives that exhibit greater α_{1A} -adrenergic blocking potency and more selectivity than available known compounds and are useful for treatment of benign prostatic hyperplasia.

It is a further object of the present invention to provide compositions containing the compounds prepared in the present invention which are useful in the treatment of benign prostatic hyperplasia.

Accordingly, objective of the present invention is achieved by synthesis of a class of piperazine derivatives of general Formula I, as shown in the accompanied drawings, its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or branched C_1 - C_4 alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl group disubstituted with the substituents independently selected from the group consisting of halogen, hydroxy, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, trifluoromethyl, nitro and trifluoroalkoxy group or (dihalodiphenyl) methyl.

Also, further object of the present invention is achieved by the synthesis of a class of piperazine derivatives of Formula I (as shown in the accompanied drawings), or its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides,

prodrugs, metabolites or their polymorphs wherein A is straight or branched C₁-C₄ alkyl chain; R is phenyl, monosubstituted phenyl group substituted with the substituents independently selected from the group consisting of chloro, fluoro, iodo, nitro, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, hexyloxy and trifluoromethyl.

The present invention also provides pharmaceutical compositions for the treatment of benign prostatic hyperplasia. These compositions comprise an effective amount of at least one of the compounds of Formula I, as shown in the accompanied drawings, or an effective amount of at least one physiologically acceptable acid addition salt thereof, with a pharmaceutically acceptable carrier.

The compounds of the present invention may be prepared following the methods as disclosed in Schemes I and II of the accompanied drawings to yield compounds of Formula I with A and R groups as defined above.

Scheme I

The compounds of the Formula I can be prepared by condensation of piperazine derivatives of Formula VII with the anhydride of Formula VI, as shown in the accompanied drawings wherein A and R are the same as defined above, preferably in a solvent selected from the group consisting of pyridine, n-butanol, benzene and xylene while refluxing.

Scheme II

The compounds of the Formula I, wherein A and R are the same as defined above, can also be synthesised following the reaction sequence as shown in Scheme II of the accompanied drawings, by condensation of 1-(ω -haloalkyl)-cis-3a,4,7,7a-tetrahydrophthalimide of Formula VIII, as shown in the accompanied drawings, wherein A is the same as defined above, with 1-substituted piperazine of the Formula IX, wherein R is the same as defined before.

An illustrative list of particular compounds prepared according to the processes of the invention is given below:

Compound

No.

Name

1. 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
2. 2-[3-{4-(3-Chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
3. 2-[3-{4-(2-Methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
4. 2-[3-{4-(4-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
5. 2-[3-{4-(3-Trifluoromethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
6. 2-[3-{4-(2-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
7. 2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
8. 2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
9. 2-[3-{4-(2-Ethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
10. 2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
11. 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
12. 2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
13. 2-[3-{4-(Phenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;

14. 2-[3-{4-(Benzyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
15. 2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
16. 2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
17. 2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
18. 2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
19. 2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
20. 2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
21. 2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
22. 2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
23. 2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
24. 2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
25. 2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
26. 2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
27. 2-[3-{4-(4-tert-Butylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
28. 2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
29. 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
30. 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-2-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;

31. 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;

Pharmaceutically acceptable non toxic acid addition salts of the compounds prepared according to the present invention having the utility of the free bases of Formula I may be formed with inorganic or organic acids, by methods well known in the art and may be used in place of free bases. Representative examples of suitable acids for formation of such acid addition salts are malic, fumaric benzoic, ascorbic, pamoic, succinic, bismethylene, salicylic, methanesulphonic ethanedisulphonic, acetic, propionic, tartaric, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfanic, phosphoric, hydrobromic and nitric acids, and the like.

The present invention also includes within its scope prodrugs of the compounds of Formula I. In general, such prodrugs will be functional derivatives of these compounds which are readily converted in vivo into the defined compounds. Conventional procedures for the selection and preparation of suitable prodrugs are known.

The invention also includes the enantiomers, diastereomers, N-oxides, pharmaceutically acceptable salts, amides and polymorphic forms of these compounds, as well as metabolites having the same activity. The invention further includes pharmaceutical compositions comprising the molecules of Formula I, or prodrugs, metabolites, enantiomers, diastereomers, N-oxides, pharmaceutically acceptable salts or polymorphic forms thereof, in combination with a pharmaceutically acceptable carrier and optionally included excipients.

In yet another aspect, this invention is directed to methods for selectively blocking α_{1A} receptors by delivering in the environment of said receptors, e.g. to the extracellular medium (or by administering to a mammal possessing said receptors) an effective amount of the compounds of the invention.

While the invention has been described by reference to specific embodiments, this was for purposes of illustration only. Numerous alternative embodiments will be apparent to those skilled in the art and are deemed to be within the scope of the invention.

The examples mentioned below demonstrate the general synthetic as well as the specific preparation for the preferred compound. The examples are given to illustrate the details of the invention and should not be constrained to limit the scope of the present invention.

EXAMPLE

Preparation of 2-[3-{4-(2-methoxyphenyl)piperazine-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione.

Scheme I

A mixture of 1-amino-3-[4-(2-methoxyphenyl)piperazine-1-yl]propane (0.498g, 2.0 mmol) and cis-1,2,3,6-tetrahydrophthalic anhydride (0.273g, 1.8mmol) was refluxed in pyridine (10ml) for about 5 hrs. After the reaction was over, solvent was removed under vacuum and the residue was dissolved in chloroform (25ml). The chloroform phase was washed with water (2 x 15ml), dried over anhydrous sodium sulphate and concentrated under vacuum. The crude compound so obtained was purified by column chromatography over silica gel (100-200 mesh) using chloroform as an eluent (yield = 0.502g, 72%).

The hydrochloride salt was prepared by the addition of molar quantity of ethereal hydrogen chloride solution to the ethereal solution of free base and collected the precipitated solid by filtration (m.p. 184-185°C).

Scheme II

A mixture of 1-(3-bromopropyl)-cis-3a, 4,7,7a-tetrahydrophthalimide (7.04g, 25.88 mmol), 1-(2-methoxyphenyl)piperazine hydrochloride (5.32g, 23.29 mmol),

potassium carbonate (7.14g, 51.76mmol) and potassium iodide (0.026g, 1.55mmol) in N, N-dimethylformamide (27ml) was heated at 75-80°C for about 12 hours. After the reaction was over, solvent was evaporated under vacuum, residue was suspended in water (130ml) and extracted the compound with dichloromethane (2 x 65ml). The combined dichloromethane layer was washed with water (2 x 30ml), dried over anhydrous sodium sulphate and concentrated the solvent under vacuum to yield 8.308g (93%) of the crude base. The compound so obtained was converted into its hydrochloride salt (m. pt. 184-185°C).

An illustrative list of the compounds of the invention which were synthesised by one or more of the above described methods is now given.

Compound

No.

Name

1. 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 184-185°C.
2. 2-[3-{4-(3-Chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 221-223°C.
3. 2-[3-{4-(2-Methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 186-187°C.
4. 2-[3-{4-(4-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 228-230°C.
5. 2-[3-{4-(3-Trifluoromethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 215-217°C.
6. 2-[3-{4-(2-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 203-204°C.
7. 2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 194-196°C.
8. 2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 163-165°C.
9. 2-[3-{4-(2-Ethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 232.5-233.5°C.

10. 2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 218.2-219°C.
11. 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 221.9 - 222.7 C.
12. 2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 231-232°C.
13. 2-[3-{4-(Phenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 231-232°C.
14. 2-[3-{4-(Benzyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 275-276°C.
15. 2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 263-265°C.
16. 2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 259.5 - 261°C.
17. 2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 248-249°C.
18. 2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 232-233°C.
19. 2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 235-236°C.
20. 2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 210-211°C.
21. 2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 226-227°C.
22. 2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 223-224°C.
23. 2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 223-224°C.
24. 2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 193-194°C.
25. 2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 165-166°C.
26. 2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 193-195 C.

27. 2-[3-{4-(4-tert-Butylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 264-265 °C.
28. 2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 267-268°C.
29. 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 219-220°C.
30. 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-2-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 184-185°C.
31. 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 246-248°C.

All the melting points reported above are uncorrected and measured by an open capillary method using Buchi 535.

PHARMACOLOGICAL TESTING RESULTS

Receptor Binding Assay

Receptor binding assays were performed using native alpha adrenoceptors. The affinity of different compounds for α_{1A} and α_{1B} adrenoceptor subtypes was evaluated by studying their ability to displace specific [3H]prazosin binding from the membranes of rat submaxillary and liver respectively (*Michel et al, Br J Pharmacol*, 98,883-889 (1989)). The binding assays were performed according to *U'Prichard et al.(Eur J Pharmacol, 50:87-89 (1978))* with minor modifications.

Submaxillary glands were isolated immediately after sacrifice. The liver was perfused with buffer (Tris HCl 50 mM, NaCl 100 mM, 10 mM EDTA pH 7.4). The tissues were homogenised in 10 volumes of buffer (Tris HCl 50 mM, NaCl 100 mM, EDTA 10 mM, pH 7.4). The homogenate was filtered through two layers of wet gauze and filtrate was centrifuged at 500g for 10min. The supernatant was subsequently centrifuged at 40,000g for 45 min. The pellet thus obtained was resuspended in the same volume of assay buffer (Tris HCl 50 mM, EDTA 5mM, pH 7.4) and were stored at -70°C until the time of assay.

The membrane homogenates (150-250 µg protein) were incubated in 250 µl of assay buffer (Tris HCl 50 mM, EDTA 5 mM, pH 7.4) at 24-25°C for 1h. Non-specific binding was determined in the presence of 300 nM prazosin. The incubation was terminated by vacuum filtration over GF/B fibre filters. The filters were then washed with ice cold 50mM Tris HCl buffer (pH 7.4). The filtermats were dried and bound radioactivity retained on filters was counted. The IC₅₀ & K_d were estimated by using the non-linear curve fitting program using G Pad Prism software. The value of inhibition constant K_i was calculated from competitive binding studies by using Cheng & Prusoff equation (Cheng & Prusoff, *Biochem Pharmacol*, 1973,22: 3099-3108), $K_i = IC_{50} / (1 + L/K_d)$ where L is the concentration of [³H]prazosin used in the particular experiment (Table I).

In Vitro Functional Studies

In order to study selectivity of action of these compounds towards different alpha adrenoceptor subtypes, the ability of these compounds to antagonise α₁ – adrenoceptor agonist induced contractile response on aorta (α_{1D}), prostate (α_{1A}) and spleen (α_{1B}) was studied. Aorta and spleen tissues were isolated from urethane anaesthetised (1.5gm/kg) male wistar rats. Isolated tissues were mounted in organ bath containing Krebs Henseleit buffer of following composition (mM) : NaCl 118; KCl 4.7; CaCl₂ 2.5; MgSO₄ 7H₂O 1.2; NaHCO₃ 25; KH₂PO₄ 1.2; glucose 11.5. Buffer was maintained at 37°C and aerated with a mixture of 95% O₂ and 5% CO₂. A resting tension of 2g (aorta) or 1g (spleen and prostate) was applied to tissues. Contractile response was monitored using a force displacement transducer and recorded on chart recorders. Tissues were allowed to equilibrate for 2 hours. At the end of equilibration period, concentration response curves to norepinephrine (aorta) and phenylepinephrine (spleen and prostate) were obtained in absence and presence of tested compound (at concentration of 0.1, 1 and 10 mM). Antagonist affinity was calculated and expressed as pK_B values in Table II.

In Vivo Uroselectivity Study:

In order to assess the uroselectivity in vivo, the effects of these compounds were studied on mean arterial pressure (MAP) and intraurethral pressure (IUP) in conscious beagle dogs as per the method of Brune et. al. (*Pharmacol* 1996, 53 :356-368). Briefly, male dogs were instrumented for chronic continuous measurement of arterial blood pressure by implanting a telemetry transmitter (TL11M2-D70-PCT, Data Sci. International, St. Paul, MN. USA) into the femoral artery, two weeks prior to the study. During the recovery period, the animal was acclimatized to stay in the sling restraint. On the day of testing, overnight fasted animal was placed in the sling restraint. A Swan-Ganz. Balloon tipped catheter was introduced into the urethra at the level of prostate and the balloon was inflated (Brune. et. al. 1996). After recording the base line readings, effect of 16 µg/kg, phenylephrine (i.v.) on MAP and IUP was recorded. The response of phenylephrine to MAP and IUP were recorded at 0.5, 1, 2, 3, 4, 6, 9 and 24 hours after the oral administration of vehicle or the test drug. The changes in MAP was recorded on line using Dataquest Software (Data Sci. International. St. Paul, MN. USA) and IUP was recorded on a Grass Polygraph (Model 7, Grass Instruments, USA). The change in phenylephrine response on MAP and IUP administration after the test drug administration was calculated as percent change of that of control values. Area under curve was calculated and the ratio of the values for MAP and IUP was used for calculating the uroselectivity (Table III)

Table I: Radioligand Binding Studies

Affinity of compounds for Alpha -1 adrenorec ptor subtyp s.

Compound No.	$\alpha_1 A$ (Rat submaxillary)	$\alpha_1 B$ (Rat liver)	Selectivity ($\alpha_1 B / \alpha_1 A$)
	Ki (nM)	Ki (nM)	
01	0.8	73	91
02	83	398	4.8
03	32.5	168	5
04	80	363	4.5
05	259	>500	2
06	36	469	13
07	183	>500	2.7
08	0.34	29	85
09	0.3	62	207
10	62	165	2.7
11	0.13	19	146
12	8.66	51.3	5.9
13	6.3	384	61
14	>500	>500	1
15	>500	>500	1
16	>500	>500	1
17	48	37	0.78
18	10	271	27
19	5.26	81	15
20	46.8	>500	11
21	>500	>500	1
22	208	>500	2.4
23	0.16	28	175
24	0.24	28	117
25	3.3	>500	>151
26	38	>500	13
27	>500	>500	1
28	>500	>500	1
29	3.45	708	205
30	48	611	13
31	2.1	232	110

Table II :**In Vitro Functional Assays :**

Compound No.	α Adrenoceptor Subtype (pK _B)			Selectivity	
	α 1A	α 1B	α 1D	α 1A/ α 1D	α 1A/ α 1B
01	9.27	7.66	8.64	4	41
08	8.93	8.40	9.05	-1.31	3.4
09	9.17	7.8	8.6	3.6	23
11	9.95	8.28	8.76	15	47
13	8.04	6.09	7.29	5.6	89
23	9.94	7.71	9.91	1	170
24	10.4	7.85	9.27	13	355
25	8.90	7.17	9.00	-1.26	54
29	7.06	5.8	7.47	-2.57	18
31	8.3	ND	7.79	3.24	

Table III: In Vivo Uroselectivity Studies in Conscious Beagle Dogs

Compound No.	Dose (μ g/kg)	Route	Area Under Curve		Uroselectivity Ratio
			MAP	IUP	
01	100	p.o	93	514	5.54
11	10	p.o	10	661	66
23	3	p.o	197	790	4
24	3	p.o.	68	522	7.6

CLAIMS

1. A process for preparing a compound of Formula I (as shown in the accompanied drawings) or its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or branched C₁-C₄ alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl group disubstituted with the substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl, nitro and trifluoroalkoxy group or (dihalodiphenyl) methyl, which comprises reacting a compound of Formula VI, as shown in the accompanied drawings, with piperazine derivatives of Formula VII, as shown in the accompanied drawings (Scheme I) wherein A and R are the same as defined above.
2. A process according to claim 1 for preparing the following compounds:
 - 2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 07)
 - 2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 08)
 - 2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione; (Compound 10)
 - 2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 12)
 - 2-[3-{4-(Benzyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 14)
 - 2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 15)
 - 2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 17)
 - 2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 18)
 - 2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 19)

- 2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 20)
 - 2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 21)
 - 2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 22)
 - 2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 26)
 - 2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 28)
3. A process for preparing a compound of Formula I (as shown in the accompanied drawings), or its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs wherein A is straight or branched C₁-C₄ alkyl chain, R is phenyl, monosubstituted phenyl group substituted with the substituents independently selected from the group consisting of chloro, fluoro, iodo, nitro, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, hexyloxy and trifluoromethyl, which comprises reacting a compound of Formula VI, with piperazine derivatives of Formula VII, as shown in the accompanied drawings (Scheme I) wherein A and R are the same as defined above.
4. A process according to claim 3 for preparing the following compounds:
- 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 01)
 - 2-[3-{4-(3-Chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 02)
 - 2-[3-{4-(2-Methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 03)
 - 2-[3-{4-(4-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 04)

- 2-[3-{4-(3-Trifluoromethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 05)
- 2-[3-{4-(2-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 06)
- 2-[3-{4-(2-Ethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 09)
- 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 11)
- 2-[3-{4-(Phenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 13)
- 2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 16)
- 2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 23)
- 2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 24)
- 2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 25)
- 2-[3-{4-(4-tert-Butylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 27)
- 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 29)
- 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-2-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 30)
- 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 31)

5. A process for preparing a compound of Formula I (as shown in the accompanied drawings) or its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or branched C₁-C₄ alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl group disubstituted with the substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl, nitro and trifluoroalkoxy

group or (dihalodiphenyl) methyl, which comprises reacting 1-(ω -haloalkyl)cis-3a,4,7,7a-tetrahydrophthalimide of Formula VIII, as shown in the accompanied drawings, wherein A is the same as defined above, with a compound of Formula IX, wherein R is the same as defined above, as shown in the Scheme II of the accompanied drawings.

6. A process according to claim 5 for preparing the following compounds.
- 2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 07)
 - 2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 08)
 - 2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione; (Compound 10)
 - 2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 12)
 - 2-[3-{4-(Benzyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 14)
 - 2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 15)
 - 2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 17)
 - 2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 18)
 - 2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 19)
 - 2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 20)
 - 2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 21)
 - 2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 22)
 - 2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 26)

- 2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 28)
7. A process for preparing a compound of Formula I (as shown in the accompanied drawings) or its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is straight or branched C₁-C₄ alkyl chain, R is phenyl, monosubstituted phenyl group substituted with the substituents independently selected from the group consisting of chloro, fluoro, iodo, nitro, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, n-propoxy, isopropoxy, hexyloxy and trifluoromethyl, which comprises reacting a compound of Formula VIII, as shown in the accompanied drawings, with the compound of Formula IX, as shown in the accompanied drawings (Scheme II) wherein A and R are the same as defined in above.
8. A process according to claim 7 for preparing the following compounds:
- 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 01)
 - 2-[3-{4-(3-Chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 02)
 - 2-[3-{4-(2-Methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 03)
 - 2-[3-{4-(4-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 04)
 - 2-[3-{4-(3-Trifluoromethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 05)
 - 2-[3-{4-(2-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 06)
 - 2-[3-{4-(2-Ethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 09)
 - 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 11)
 - 2-[3-{4-(Phenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 13)

- 2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 16)
 - 2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 23)
 - 2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 24)
 - 2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 25)
 - 2-[3-{4-(4-tert-Butylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 27)
 - 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 29)
 - 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-2-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 30)
 - 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 31)
9. A method of selectively antagonizing α_1 -adrenergic receptors in a mammal comprising administering to said mammal a compound prepared according to any of the preceding claims.
 10. A method for treating benign prostatic hyperplasia in a mammal comprising administering to said mammal a compound prepared according to any of the preceding claims.
 11. A pharmaceutical composition comprising the compound prepared according to any of the preceding claims and a pharmaceutical acceptable carrier.
 12. A method of selectively antagonizing α_1 -adrenergic receptors in a mammal comprising the step of administering to the said mammal the pharmaceutical composition according to claim 11.

13. A method for treating benign prostatic hyperplasia in a mammal comprising the step of administering to the said mammal the pharmaceutical composition according to claim 11.
14. The process for the preparation of the compounds of Formula I, as shown in the accompanied drawings substantially as herein described and illustrated by the examples herein.

Dated this 30th day of November, 2000.

For Ranbaxy Laboratories Limited




**(S K Patawari)
Company Secretary**

Ranbaxy Laboratories Limited.

No. of sheets = 07

Application No.

Sheet 01 of 07



FORMULA - I

1097 DEL 00
30 DEC 2000
Nov

ORIGINAL

For Ranbaxy Laboratories Limited


Seay
(S K Patawari)
Company Secretary

Ranbaxy Laboratories Limited

No. of sheets = 07

Application No.

Sheet 02 of 07



FORMULA - II

1037 DEL
30 DEC 2000

ORIGINAL

For Ranbaxy Laboratories Limited


Seay
(S K Patawari)
Company Secretary

Ranbaxy Laboratories Limited

No. of sheets = 07

Application No.

Sheet 03 of 07



FORMULA - III

1097 DEL 00
30 DEC 2000
Not
DEC

ORIGINAL

For Ranbaxy Laboratories Limited


Sen
(S K Patawari)
Company Secretary

Ranbaxy Laboratories Limited

No. of sheets = 07

Application No.

Sheet 04 of 07



FORMULA - IV

1097 DEL 00
30 NOV 2000

ORIGINAL

For Ranbaxy Laboratories Limited


(S K Patawari)
Company Secretary

Ranbaxy Laboratories Limited


No. of sheets = 07

Application No.

Sheet 05 of 07

1097 DEL 00

30 DEC 2000




FORMULA - V

ORIGINAL

For Ranbaxy Laboratories Limited


S K Patawari
(S K Patawari)
Company Secretary

SCHEME - I




FORMULA VI

+



FORMULA VII

Solvent, Δ



FORMULA I


10-7 DEL 00
30 DEC 2000
No. ✓

ORIGINAL

For Ranbaxy Laboratories Limited


S K Patawari
(S K Patawari)
Company Secretary

SCHEME - II




FORMULA VIII

+



FORMULA IX

Solvent, Δ



FORMULA I

10 97 DEL 00

Not
30 DEC 2000

ORIGINAL

For Ranbaxy Laboratories Limited

(S K Patawari)
Company Secretary

THIS PAGE BLANK (USPTO)